-The Business Standard   New climate report means big changes to future agreements Two distinct features set the third report of the United Nations Intergovernmental Panel on Climate Change (IPCC) apart from its two earlier instalments. First, even as the report points out that governments have not done enough to curb, let alone reverse, the rise in the emissions of greenhouse gases (GHGs), it does not seek to instil a sense of despair....

-The Business Standard     Institutions such as World Bank and Asian Development Bank (ADB) are considered the panacea of all ills that developing countries like India face. Although the amount of money these institutions lend is small, their influence on the economy is high. They continue to be the benchmark for social and environmental policies, good governance, climate change, corruption and so on. A look at some of the reports of these...

-The Indian Express   Political parties must do more than just pay lip service to universal healthcare in their election manifestos. The governance of the public health sector has become more complex than we imagine. To improve overall health, the sector will have to coordinate and collaborate with other sectors, nationally and regionally, and with several stakeholders. There is no sector that does not have an impact (positive or negative) on public health. What...

-Live Mint   FDI in retail and modernization of agriculture are two faces of the same coin In the season of elections animal spirits rule. India's equity markets have been ebullient for some time now. Spurred by a robust inflow of foreign investment capital, markets have reacted favourably. A lot now depends on the ability of the next government to enact meaningful structural reforms, especially in a sector such as agriculture that requires...

-The Hindu A strong whistle-blower protection law in India would expose financial corruption in a way that reinforces ethical business practices In 2013, generic pharmaceutical company Ranbaxy pleaded guilty to seven criminal felonies for drug manufacturing fraud and agreed to cough up an unprecedented $500 million in fines. The case against Ranbaxy was significant not only for being a successful prosecution of a powerful India corporation. It also marked the triumph of Dinesh...